Michael A. Friedman, M.D.
An executive officer from a California Research Institute
Appointed by the Treasurer
Dr. Michael A. Friedman in 2014 completed a decade of service as the Chief Executive Officer and Director, Comprehensive Cancer Center, Irell & Manella Cancer Center’s Distinguished Chair of City of Hope, a cancer research and treatment institution dedicated to innovation in basic and clinical biomedical research and delivery of exceptional patient care. Before this he was a senior vice president of research and development at Pharmacia Corporation. Following the events of September 11, 2001, he simultaneously served as chief medical officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America. Dr. Friedman previously served as the U.S. Food and Drug Administration (FDA) Deputy Commissioner and was then tapped by the Clinton administration to serve as acting commissioner of the FDA. He helped to streamline the FDA’s review and approval process and protect the nation’s food and drug supply.
In 1983, Dr. Friedman joined the Division of Cancer Treatment at the National Cancer Institute, and went on to become the associate director of the Cancer Therapy Evaluation Program. Before joining the NCI, he spent nearly a decade at the University of California at San Francisco, as an associate professor of medicine directing the Cancer Research Institute. He joined the U.S. Public Health Service in 1970, ultimately attaining the rank of Rear Admiral and has served as an active duty and now reserve officer. He has received a number of commendations, including the Surgeon General’s Medallion, the FDA Commissioner’s Special Citation and the PHS Distinguished Service Medal.
Dr. Friedman received his Bachelor of Arts degree, magna cum laude, from Tulane University and a Doctorate in Medicine from the University of Texas. He completed postdoctoral training at Stanford University and the National Cancer Institute, and is board certified in Internal Medicine and Medical Oncology.
Currently, in addition to his efforts on behalf of City of Hope, he serves as a director on several corporate boards and is a trustee of Tulane University and serves on the California Stem Cell Oversight Board.
Theodore G. Krontiris, MD, PhD
Director Emeritus, Comprehensive Cancer Center
Distinguished Professor, Molecular Medicine
Theodore Krontiris, MD, PhD, joined City of Hope (COH) in 1996 as chair of a newly established Department of Molecular Medicine; he was Executive Vice President, Medical and Scientific Affairs, and Director of COH’s NCI-designated Comprehensive Cancer Center from 2001 to 2007. Prior to coming to COH, Dr. Krontiris held several medical and teaching positions at Tufts University School of Medicine and Tufts New England Medical Center Hospitals, where he was founding director of the Graduate Program in Genetics at the Sackler Graduate School. He received his medical degree and PhD from the Albert Einstein College of Medicine in New York, as well as residency and fellowship training at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute in Boston.